These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24453294)

  • 1. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
    Seah DS; Luis IV; Macrae E; Sohl J; Litsas G; Winer EP; Lin NU; Burstein HJ
    J Natl Compr Canc Netw; 2014 Jan; 12(1):71-80. PubMed ID: 24453294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
    Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
    Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Zhang L; Yu Q; Wu XC; Hsieh MC; Loch M; Chen VW; Fontham E; Ferguson T
    Breast Cancer Res Treat; 2018 May; 169(1):175-187. PubMed ID: 29368311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
    Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P
    Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Mamet R; Burstein HJ; Edge SB; Gonzalez-Angulo AM; Moy B; Rugo HS; Theriault RL; Weeks JC; Winer EP; Lin NU
    J Clin Oncol; 2014 Jul; 32(20):2142-50. PubMed ID: 24888816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
    Shah AN; Flaum L; Helenowski I; Santa-Maria CA; Jain S; Rademaker A; Nelson V; Tsarwhas D; Cristofanilli M; Gradishar W
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32060053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
    Bachelot T; Filleron T; Bieche I; Arnedos M; Campone M; Dalenc F; Coussy F; Sablin MP; Debled M; Lefeuvre-Plesse C; Goncalves A; Reynier MM; Jacot W; You B; Barthelemy P; Verret B; Isambert N; Tchiknavorian X; Levy C; Thery JC; L'Haridon T; Ferrero JM; Mege A; Del Piano F; Rouleau E; Tran-Dien A; Adam J; Lusque A; Jimenez M; Jacquet A; Garberis I; Andre F
    Nat Med; 2021 Feb; 27(2):250-255. PubMed ID: 33462450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
    Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
    Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
    Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
    Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
    Yang SX; Polley EC
    Breast Cancer Res Treat; 2019 Jun; 175(2):287-295. PubMed ID: 30746635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
    Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum-based chemotherapy in triple-negative advanced breast cancer.
    Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
    Breast Cancer Res Treat; 2014 Aug; 146(3):567-72. PubMed ID: 25001611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.